In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
Doximity Inc (NYSE: DOCS) closed the day trading at $45.68 down -0.54% from the previous closing price of $45.93. In other words, the price has decreased by -$0.54 from its previous closing price. On the day, 4.53 million shares were traded. DOCS stock price reached its highest trading level at $46.585 during the session, while it also had its lowest trading level at $45.455.
Ratios:
For a better understanding of DOCS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.79 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 27.56. For the most recent quarter (mrq), Quick Ratio is recorded 7.75 and its Current Ratio is at 7.75. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On November 13, 2025, BMO Capital Markets started tracking the stock assigning a Market Perform rating and target price of $55.
BofA Securities Upgraded its Neutral to Buy on October 27, 2025, while the target price for the stock was maintained at $82.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 01 ’25 when Wampler Kira Scherer sold 2,000 shares for $50.71 per share. The transaction valued at 101,420 led to the insider holds 19,839 shares of the business.
KIRA WAMPLER bought 2,000 shares of DOCS for $101,420 on Dec 01 ’25. On Nov 21 ’25, another insider, Cabral Timothy S, who serves as the Director of the company, sold 10,000 shares for $50.00 each. As a result, the insider received 500,000 and left with 3,221 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DOCS now has a Market Capitalization of 8600230912 and an Enterprise Value of 7780201472. As of this moment, Doximity’s Price-to-Earnings (P/E) ratio for their current fiscal year is 36.44, and their Forward P/E ratio for the next fiscal year is 26.56. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.33. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.84 while its Price-to-Book (P/B) ratio in mrq is 7.84. Its current Enterprise Value per Revenue stands at 12.522 whereas that against EBITDA is 30.609.
Stock Price History:
The Beta on a monthly basis for DOCS is 1.38, which has changed by -0.13175803 over the last 52 weeks, in comparison to a change of 0.13844287 over the same period for the S&P500. Over the past 52 weeks, DOCS has reached a high of $85.21, while it has fallen to a 52-week low of $45.29. The 50-Day Moving Average of the stock is -24.73%, while the 200-Day Moving Average is calculated to be -25.14%.
Shares Statistics:
Over the past 3-months, DOCS traded about 1.76M shares per day on average, while over the past 10 days, DOCS traded about 2354270 shares per day. A total of 137.19M shares are outstanding, with a floating share count of 133.41M. Insiders hold about 29.14% of the company’s shares, while institutions hold 66.19% stake in the company. Shares short for DOCS as of 1763078400 were 5170607 with a Short Ratio of 2.94, compared to 1760486400 on 4601746. Therefore, it implies a Short% of Shares Outstanding of 5170607 and a Short% of Float of 3.85.
Earnings Estimates
The firm’s stock currently is rated by 17.0 analysts. The consensus estimate for the next quarter is $0.32, with high estimates of $0.39 and low estimates of $0.26.
Analysts are recommending an EPS of between $1.67 and $1.35 for the fiscal current year, implying an average EPS of $1.57. EPS for the following year is $1.72, with 18.0 analysts recommending between $2.04 and $1.47.
Revenue Estimates
18 analysts predict $181.63M in revenue for. The current quarter. It ranges from a high estimate of $192.21M to a low estimate of $180.3M. As of. The current estimate, Doximity Inc’s year-ago sales were $168.6MFor the next quarter, 18 analysts are estimating revenue of $150.34M. There is a high estimate of $158.71M for the next quarter, whereas the lowest estimate is $147.8M.
A total of 20 analysts have provided revenue estimates for DOCS’s current fiscal year. The highest revenue estimate was $664.29M, while the lowest revenue estimate was $625M, resulting in an average revenue estimate of $644.96M. In the same quarter a year ago, actual revenue was $570.4MBased on 20 analysts’ estimates, the company’s revenue will be $716.33M in the next fiscal year. The high estimate is $773.46M and the low estimate is $688.7M.
